-
1
-
-
84876550739
-
Achievement of goals in U. S. Diabetes care, 1999-2010
-
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U. S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-1624
-
(2013)
N Engl J Med
, vol.368
, pp. 1613-1624
-
-
Ali, M.K.1
Bullard, K.M.2
Saaddine, J.B.3
Cowie, C.C.4
Imperatore, G.5
Gregg, E.W.6
-
2
-
-
33846025092
-
Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
-
Buse JB, Ginsberg HN, Bakris GL, et al.; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-172
-
(2007)
Diabetes Care
, vol.30
, pp. 162-172
-
-
American Heart Association1
American Diabetes Association2
Buse, J.B.3
Ginsberg, H.N.4
Bakris, G.L.5
-
3
-
-
38949210220
-
Effect of a multifactorial intervention on mortality in type 2 diabetes
-
Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
-
(2008)
N Engl J Med
, vol.358
, pp. 580-591
-
-
Gaede, P.1
Lund-Andersen, H.2
Parving, H.-H.3
Pedersen, O.4
-
5
-
-
0035829087
-
Is "isolated home" hypertension as opposed to "isolated office" hypertension a sign of greater cardiovascular risk?
-
Bobrie G, Genès N, Vaur L, et al. Is "isolated home" hypertension as opposed to "isolated office" hypertension a sign of greater cardiovascular risk? Arch Intern Med 2001;161:2205-2211
-
(2001)
Arch Intern Med
, vol.161
, pp. 2205-2211
-
-
Bobrie, G.1
Genès, N.2
Vaur, L.3
-
6
-
-
17144375670
-
Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study
-
Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:1777-1783
-
(2005)
Circulation
, vol.111
, pp. 1777-1783
-
-
Sega, R.1
Facchetti, R.2
Bombelli, M.3
-
7
-
-
84899468978
-
Blood pressure targets for hypertension in people with diabetes mellitus
-
Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013;10:CD008277
-
(2013)
Cochrane Database Syst Rev
, vol.10
, pp. CD008277
-
-
Arguedas, J.A.1
Leiva, V.2
Wright, J.M.3
-
8
-
-
84893549987
-
2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)
-
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520
-
(2014)
JAMA
, vol.311
, pp. 507-520
-
-
James, P.A.1
Oparil, S.2
Carter, B.L.3
-
9
-
-
84867144380
-
Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: Systematic review and meta-analysis
-
McBrien K, Rabi DM, Campbell N, et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012;172:1296-1303
-
(2012)
Arch Intern Med
, vol.172
, pp. 1296-1303
-
-
McBrien, K.1
Rabi, D.M.2
Campbell, N.3
-
10
-
-
77951735232
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus
-
Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
-
(2010)
N Engl J Med
, vol.362
, pp. 1575-1585
-
-
Cushman, W.C.1
Evans, G.W.2
Byington, R.P.3
-
11
-
-
34548420712
-
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial
-
Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840
-
(2007)
Lancet
, vol.370
, pp. 829-840
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
-
12
-
-
84907862963
-
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
-
Zoungas S, Chalmers J, Neal B, et al.; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392-1406
-
(2014)
N Engl J Med
, vol.371
, pp. 1392-1406
-
-
Zoungas, S.1
Chalmers, J.2
Neal, B.3
-
13
-
-
84948439672
-
A randomized trial of intensive versus standard blood-pressure control
-
9 November, Epub ahead of print
-
SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 9 November 2015 [Epub ahead of print]. DOI: 10.1056/NEJMoa1511939
-
(2015)
N Engl J Med.
-
-
-
14
-
-
0032528726
-
Hypertension Optimal Treatment (HOT) trial
-
Cruickshank JM. Hypertension Optimal Treatment (HOT) trial. Lancet 1998;352:573-574
-
(1998)
Lancet
, vol.352
, pp. 573-574
-
-
Cruickshank, J.M.1
-
15
-
-
84922567942
-
Blood pressure lowering in type 2 diabetes: A systematic review and metaanalysis
-
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015;313:603-615
-
(2015)
JAMA
, vol.313
, pp. 603-615
-
-
Emdin, C.A.1
Rahimi, K.2
Neal, B.3
Callender, T.4
Perkovic, V.5
Patel, A.6
-
16
-
-
0035804277
-
Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet
-
Sacks FM, Svetkey LP, Vollmer WM, et al.; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10
-
(2001)
N Engl J Med
, vol.344
, pp. 3-10
-
-
Sacks, F.M.1
Svetkey, L.P.2
Vollmer, W.M.3
-
17
-
-
0038460302
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report
-
Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
-
(2003)
JAMA
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
18
-
-
0031944128
-
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
-
Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603
-
(1998)
Diabetes Care
, vol.21
, pp. 597-603
-
-
Tatti, P.1
Pahor, M.2
Byington, R.P.3
-
19
-
-
0032485350
-
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulindependent diabetes and hypertension
-
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulindependent diabetes and hypertension. N Engl J Med 1998;338:645-652
-
(1998)
N Engl J Med
, vol.338
, pp. 645-652
-
-
Estacio, R.O.1
Jeffers, B.W.2
Hiatt, W.R.3
Biggerstaff, S.L.4
Gifford, N.5
Schrier, R.W.6
-
20
-
-
34547232484
-
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial
-
Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007;3:428-438
-
(2007)
Nat Clin Pract Nephrol
, vol.3
, pp. 428-438
-
-
Schrier, R.W.1
Estacio, R.O.2
Mehler, P.S.3
Hiatt, W.R.4
-
21
-
-
0344373794
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
-
22
-
-
0031044480
-
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
-
Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745
-
(1997)
JAMA
, vol.277
, pp. 739-745
-
-
Psaty, B.M.1
Smith, N.L.2
Siscovick, D.S.3
-
23
-
-
0034700790
-
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
-
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
-
(2000)
Lancet
, vol.355
, pp. 253-259
-
-
-
24
-
-
0041909380
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: The CHARM-Alternative trial
-
Granger CB, McMurray JJV, Yusuf S, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776
-
(2003)
Lancet
, vol.362
, pp. 772-776
-
-
Granger, C.B.1
McMurray, J.J.V.2
Yusuf, S.3
-
25
-
-
0041408235
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial
-
McMurray JJV, Ostergren J, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771
-
(2003)
Lancet
, vol.362
, pp. 767-771
-
-
McMurray, J.J.V.1
Ostergren, J.2
Swedberg, K.3
-
26
-
-
0042410539
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme
-
Pfeffer MA, Swedberg K, Granger CB, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766
-
(2003)
Lancet
, vol.362
, pp. 759-766
-
-
Pfeffer, M.A.1
Swedberg, K.2
Granger, C.B.3
-
27
-
-
0037160969
-
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Lindholm LH, Ibsen H, Dahlöf B, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010
-
(2002)
Lancet
, vol.359
, pp. 1004-1010
-
-
Lindholm, L.H.1
Ibsen, H.2
Dahlöf, B.3
-
28
-
-
0037387809
-
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
-
Berl T, Hunsicker LG, Lewis JB, et al.; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-549
-
(2003)
Ann Intern Med
, vol.138
, pp. 542-549
-
-
Irbesartan Diabetic Nephropathy Trial1
Berl, T.2
Hunsicker, L.G.3
Lewis, J.B.4
-
29
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
-
(2008)
N Engl J Med
, vol.358
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
-
30
-
-
57349138291
-
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
-
Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
-
(2008)
N Engl J Med
, vol.359
, pp. 2417-2428
-
-
Jamerson, K.1
Weber, M.A.2
Bakris, G.L.3
-
31
-
-
80051976276
-
Influence of time of day of blood pressurelowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes
-
Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressurelowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011;34:1270-1276
-
(2011)
Diabetes Care
, vol.34
, pp. 1270-1276
-
-
Hermida, R.C.1
Ayala, D.E.2
Mojón, A.3
Fernández, J.R.4
-
32
-
-
80155143510
-
Evening versus morning dosing regimen drug therapy for hypertension
-
Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011;10:CD004184
-
(2011)
Cochrane Database Syst Rev
, vol.10
, pp. CD004184
-
-
Zhao, P.1
Xu, P.2
Wan, C.3
Wang, Z.4
-
33
-
-
0029893242
-
Treatment of hypertension in pregnant women
-
Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996;335:257-265
-
(1996)
N Engl J Med
, vol.335
, pp. 257-265
-
-
Sibai, B.M.1
-
34
-
-
26244432388
-
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins
-
Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
-
(2005)
Lancet
, vol.366
, pp. 1267-1278
-
-
Baigent, C.1
Keech, A.2
Kearney, P.M.3
-
35
-
-
84864832599
-
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials
-
Mihaylova B, Emberson J, Blackwell L, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-590
-
(2012)
Lancet
, vol.380
, pp. 581-590
-
-
Mihaylova, B.1
Emberson, J.2
Blackwell, L.3
-
36
-
-
1842326783
-
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
-
Pyǧorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620
-
(1997)
Diabetes Care
, vol.20
, pp. 614-620
-
-
Pyǧorälä, K.1
Pedersen, T.R.2
Kjekshus, J.3
Faergeman, O.4
Olsson, A.G.5
Thorgeirsson, G.6
-
37
-
-
0037840242
-
MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial
-
Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016
-
(2003)
Lancet
, vol.361
, pp. 2005-2016
-
-
Collins, R.1
Armitage, J.2
Parish, S.3
Sleigh, P.4
Peto, R.5
-
38
-
-
0032497945
-
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial
-
Goldberg RB, Mellies MJ, Sacks FM, et al.; The CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998;98:2513-2519
-
(1998)
Circulation
, vol.98
, pp. 2513-2519
-
-
Goldberg, R.B.1
Mellies, M.J.2
Sacks, F.M.3
-
39
-
-
33746428470
-
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study
-
Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-1226
-
(2006)
Diabetes Care
, vol.29
, pp. 1220-1226
-
-
Shepherd, J.1
Barter, P.2
Carmena, R.3
-
40
-
-
20944448451
-
Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA)
-
Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-1157
-
(2005)
Diabetes Care
, vol.28
, pp. 1151-1157
-
-
Sever, P.S.1
Poulter, N.R.2
Dahlöf, B.3
-
41
-
-
33746431474
-
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)
-
Knopp RH, D'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-1485
-
(2006)
Diabetes Care
, vol.29
, pp. 1478-1485
-
-
Knopp, R.H.1
D'Emden, M.2
Smilde, J.G.3
Pocock, S.J.4
-
42
-
-
4344683381
-
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
-
Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
-
(2004)
Lancet
, vol.364
, pp. 685-696
-
-
Colhoun, H.M.1
Betteridge, D.J.2
Durrington, P.N.3
-
43
-
-
38049033935
-
Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: A meta-analysis
-
Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-125
-
(2008)
Lancet
, vol.371
, pp. 117-125
-
-
Kearney, P.M.1
Blackwell, L.2
Collins, R.3
-
45
-
-
84878773567
-
Risk of incident diabetes among patients treated with statins: Population based study
-
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610
-
(2013)
BMJ
, vol.346
, pp. f2610
-
-
Carter, A.A.1
Gomes, T.2
Camacho, X.3
Juurlink, D.N.4
Shah, B.R.5
Mamdani, M.M.6
-
46
-
-
33750135569
-
Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem
-
Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006;145:520-530
-
(2006)
Ann Intern Med
, vol.145
, pp. 520-530
-
-
Hayward, R.A.1
Hofer, T.P.2
Vijan, S.3
-
47
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
-
(2004)
N Engl J Med
, vol.350
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
48
-
-
4544243333
-
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
-
De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316
-
(2004)
JAMA
, vol.292
, pp. 1307-1316
-
-
De Lemos, J.A.1
Blazing, M.A.2
Wiviott, S.D.3
-
49
-
-
10744225301
-
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial
-
Nissen SE, Tuzcu EM, Schoenhagen P, et al.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080
-
(2004)
JAMA
, vol.291
, pp. 1071-1080
-
-
Nissen, S.E.1
Tuzcu, E.M.2
Schoenhagen, P.3
-
50
-
-
84927172859
-
Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association
-
De Ferranti SD, De Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation 2014;130:1110-1130
-
(2014)
Circulation
, vol.130
, pp. 1110-1130
-
-
De Ferranti, S.D.1
De Boer, I.H.2
Fonseca, V.3
-
51
-
-
2942627194
-
Pharmacogenetic study of statin therapy and cholesterol reduction
-
Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004;291:2821-2827
-
(2004)
JAMA
, vol.291
, pp. 2821-2827
-
-
Chasman, D.I.1
Posada, D.2
Subrahmanyan, L.3
Cook, N.R.4
Stanton, V.P.5
Ridker, P.M.6
-
52
-
-
84858222560
-
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: An observational study
-
Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012;28:371-378
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 371-378
-
-
Meek, C.1
Wierzbicki, A.S.2
Jewkes, C.3
-
53
-
-
84931411520
-
Ezetimibe added to statin therapy after acute coronary syndromes
-
Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-2397
-
(2015)
N Engl J Med
, vol.372
, pp. 2387-2397
-
-
Cannon, C.P.1
Blazing, M.A.2
Giugliano, R.P.3
-
54
-
-
84923845326
-
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
-
Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014;8:554-561
-
(2014)
J Clin Lipidol
, vol.8
, pp. 554-561
-
-
Moriarty, P.M.1
Jacobson, T.A.2
Bruckert, E.3
-
55
-
-
84935001755
-
Safety and efficacy of anti-PCSK9 antibodies: Ameta-analysis of 25 randomized, controlled trials
-
Zhang X-L, Zhu Q-Q, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: ameta-analysis of 25 randomized, controlled trials. BMC Med 2015;13:123
-
(2015)
BMC Med
, vol.13
, pp. 123
-
-
Zhang, X.-L.1
Zhu, Q.-Q.2
Zhu, L.3
-
56
-
-
84866146620
-
Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline
-
Berglund L, Brunzell JD, Goldberg AC, et al.; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-2989
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 2969-2989
-
-
Endocrine Society1
Berglund, L.2
Brunzell, J.D.3
Goldberg, A.C.4
-
57
-
-
34547858847
-
Highdensity lipoprotein as a therapeutic target: A systematic review
-
Singh IM, Shishehbor MH, Ansell BJ. Highdensity lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-798
-
(2007)
JAMA
, vol.298
, pp. 786-798
-
-
Singh, I.M.1
Shishehbor, M.H.2
Ansell, B.J.3
-
58
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
Keech A, Simes RJ, Barter P, et al.; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
-
(2005)
Lancet
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
59
-
-
11144239674
-
Reporting rate of rhabdomyolysis with fenofibrate 1 statin versus gemfibrozil 1 any statin
-
Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate 1 statin versus gemfibrozil 1 any statin. Am J Cardiol 2005;95:120-122
-
(2005)
Am J Cardiol
, vol.95
, pp. 120-122
-
-
Jones, P.H.1
Davidson, M.H.2
-
60
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
61
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
Boden WE, Probstfield JL, Anderson T, et al.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267
-
(2011)
N Engl J Med
, vol.365
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
-
62
-
-
70349664292
-
Statin therapy and risk of developing type 2 diabetes: A meta-analysis
-
Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-1929
-
(2009)
Diabetes Care
, vol.32
, pp. 1924-1929
-
-
Rajpathak, S.N.1
Kumbhani, D.J.2
Crandall, J.3
Barzilai, N.4
Alderman, M.5
Ridker, P.M.6
-
63
-
-
77549087054
-
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
-
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742
-
(2010)
Lancet
, vol.375
, pp. 735-742
-
-
Sattar, N.1
Preiss, D.2
Murray, H.M.3
-
64
-
-
84864861863
-
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial
-
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-571
-
(2012)
Lancet
, vol.380
, pp. 565-571
-
-
Ridker, P.M.1
Pradhan, A.2
MacFadyen, J.G.3
Libby, P.4
Glynn, R.J.5
-
65
-
-
84888265005
-
Statins and cognitive function: A systematic review
-
Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013;159:688-697
-
(2013)
Ann Intern Med
, vol.159
, pp. 688-697
-
-
Richardson, K.1
Schoen, M.2
French, B.3
-
66
-
-
65849268320
-
Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials
-
Baigent C, Blackwell L, Collins R, et al.; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860
-
(2009)
Lancet
, vol.373
, pp. 1849-1860
-
-
Baigent, C.1
Blackwell, L.2
Collins, R.3
-
67
-
-
84862119222
-
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
-
Perk J, De Backer G, Gohlke H, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701
-
(2012)
Eur Heart J
, vol.33
, pp. 1635-1701
-
-
Perk, J.1
De Backer, G.2
Gohlke, H.3
-
68
-
-
56149113603
-
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial
-
Ogawa H, Nakayama M, Morimoto T, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141
-
(2008)
JAMA
, vol.300
, pp. 2134-2141
-
-
Ogawa, H.1
Nakayama, M.2
Morimoto, T.3
-
69
-
-
54949131747
-
The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
-
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840
-
(2008)
BMJ
, vol.337
, pp. a1840
-
-
Belch, J.1
MacCuish, A.2
Campbell, I.3
Cobbe, S.4
Taylor, R.5
Prescott, R.6
-
70
-
-
74449086639
-
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
-
Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;87:211-218
-
(2010)
Diabetes Res Clin Pract
, vol.87
, pp. 211-218
-
-
Zhang, C.1
Sun, A.2
Zhang, P.3
-
71
-
-
71749105108
-
Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials
-
De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
-
(2009)
BMJ
, vol.339
, pp. b4531
-
-
De Berardis, G.1
Sacco, M.2
Strippoli, G.F.3
-
72
-
-
33645128628
-
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis
-
Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
-
(2006)
Ann Intern Med
, vol.144
, pp. 326-336
-
-
Pignone, M.1
Earnshaw, S.2
Tice, J.A.3
Pletcher, M.J.4
-
73
-
-
77956076027
-
Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation
-
Pignone M, Alberts MJ, Colwell JA, et al.; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395-1402
-
(2010)
Diabetes Care
, vol.33
, pp. 1395-1402
-
-
American Diabetes Association1
American Heart Association2
American College of Cardiology Foundation3
Pignone, M.4
Alberts, M.J.5
Colwell, J.A.6
-
74
-
-
84924527309
-
Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: A systematic review and meta-analysis
-
Huxley RR, Peters SAE, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3:198-206
-
(2015)
Lancet Diabetes Endocrinol
, vol.3
, pp. 198-206
-
-
Huxley, R.R.1
Peters, S.A.E.2
Mishra, G.D.3
Woodward, M.4
-
75
-
-
84904742540
-
Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858, 507 individuals and 28, 203 coronary events
-
Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858, 507 individuals and 28, 203 coronary events. Diabetologia 2014;57:1542-1551
-
(2014)
Diabetologia
, vol.57
, pp. 1542-1551
-
-
Peters, S.A.1
Huxley, R.R.2
Woodward, M.3
-
76
-
-
84896715351
-
Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middleaged adults
-
Kalyani RR, Lazo M, Ouyang P, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middleaged adults. Diabetes Care 2014;37:830-838
-
(2014)
Diabetes Care
, vol.37
, pp. 830-838
-
-
Kalyani, R.R.1
Lazo, M.2
Ouyang, P.3
-
77
-
-
84901831131
-
Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775, 385 individuals and 12, 539 strokes
-
Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775, 385 individuals and 12, 539 strokes. Lancet 2014;383:1973-1980
-
(2014)
Lancet
, vol.383
, pp. 1973-1980
-
-
Peters, S.A.1
Huxley, R.R.2
Woodward, M.3
-
78
-
-
84930672019
-
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease
-
Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One 2015;10:e0126767
-
(2015)
PLoS One
, vol.10
, pp. e0126767
-
-
Larsen, S.B.1
Grove, E.L.2
Neergaard-Petersen, S.3
Würtz, M.4
Hvas, A.M.5
Kristensen, S.D.6
-
79
-
-
34248352504
-
Aspirin dose for the prevention of cardiovascular disease: A systematic review
-
Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018-2024
-
(2007)
JAMA
, vol.297
, pp. 2018-2024
-
-
Campbell, C.L.1
Smyth, S.2
Montalescot, G.3
Steinhubl, S.R.4
-
80
-
-
37249068049
-
Platelet activation and atherothrombosis
-
Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494
-
(2007)
N Engl J Med
, vol.357
, pp. 2482-2494
-
-
Davì, G.1
Patrono, C.2
-
81
-
-
84955310958
-
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes
-
4 June, Epub ahead of print
-
Bethel MA, Harrison P, Sourij H, et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes. Diabet Med. 4 June 2015 [Epub ahead of print]. DOI: 10.1111/dme.12828
-
(2015)
Diabet Med.
-
-
Bethel, M.A.1
Harrison, P.2
Sourij, H.3
-
82
-
-
84856794168
-
Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Vandvik PO, Lincoff AM, Gore JM, et al.; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl.):e637S-e668S
-
(2012)
Chest
, vol.141
, pp. e637S-e668S
-
-
American College of Chest Physicians1
Vandvik, P.O.2
Lincoff, A.M.3
Gore, J.M.4
-
83
-
-
34247113737
-
Optimal medical therapy with or without PCI for stable coronary disease
-
Boden WE, O'Rourke RA, Teo KK, et al.; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516
-
(2007)
N Engl J Med
, vol.356
, pp. 1503-1516
-
-
Boden, W.E.1
O'Rourke, R.A.2
Teo, K.K.3
-
84
-
-
67149142042
-
A randomized trial of therapies for type 2 diabetes and coronary artery disease
-
BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515
-
(2009)
N Engl J Med
, vol.360
, pp. 2503-2515
-
-
-
85
-
-
36048965509
-
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study
-
Wackers FJT, Chyun DA, Young LH, et al.; Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007;30:2892-2898
-
(2007)
Diabetes Care
, vol.30
, pp. 2892-2898
-
-
Wackers, F.J.T.1
Chyun, D.A.2
Young, L.H.3
-
86
-
-
52449104073
-
Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: The PREDICT study
-
Elkeles RS, Godsland IF, Feher MD, et al.; PREDICT Study Group. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J 2008;29:2244-2251
-
(2008)
Eur Heart J
, vol.29
, pp. 2244-2251
-
-
Elkeles, R.S.1
Godsland, I.F.2
Feher, M.D.3
-
87
-
-
2342428983
-
Prognostic value of coronary artery calcium screening in subjects with and without diabetes
-
Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004;43:1663-1669
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 1663-1669
-
-
Raggi, P.1
Shaw, L.J.2
Berman, D.S.3
Callister, T.Q.4
-
88
-
-
32044446172
-
Risk stratification in uncomplicated type 2 diabetes: Prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy
-
Anand DV, Lim E, Hopkins D, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006;27:713-721
-
(2006)
Eur Heart J
, vol.27
, pp. 713-721
-
-
Anand, D.V.1
Lim, E.2
Hopkins, D.3
-
89
-
-
64749092606
-
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial
-
Young LH, Wackers FJT, Chyun DA, et al.; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:1547-1555
-
(2009)
JAMA
, vol.301
, pp. 1547-1555
-
-
Young, L.H.1
Wackers, F.J.T.2
Chyun, D.A.3
-
90
-
-
3342948360
-
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study
-
Wackers FJT, Young LH, Inzucchi SE, et al.; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004;27:1954-1961
-
(2004)
Diabetes Care
, vol.27
, pp. 1954-1961
-
-
Wackers, F.J.T.1
Young, L.H.2
Inzucchi, S.E.3
-
91
-
-
29344470555
-
Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus
-
Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:65-71
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 65-71
-
-
Scognamiglio, R.1
Negut, C.2
Ramondo, A.3
Tiengo, A.4
Avogaro, A.5
-
92
-
-
77956091474
-
Prognostic value of coronary computed tomographic angiography in diabetic patients without known coronary artery disease
-
Hadamitzky M, Hein F, Meyer T, et al. Prognostic value of coronary computed tomographic angiography in diabetic patients without known coronary artery disease. Diabetes Care 2010;33:1358-1363
-
(2010)
Diabetes Care
, vol.33
, pp. 1358-1363
-
-
Hadamitzky, M.1
Hein, F.2
Meyer, T.3
-
93
-
-
70249112224
-
Assessment of subclinical coronary atherosclerosis in asymptomatic patients with type 2 diabetes mellitus with single photon emission computed tomography and coronary computed tomography angiography
-
Choi E-K, Chun EJ, Choi S-I, et al. Assessment of subclinical coronary atherosclerosis in asymptomatic patients with type 2 diabetes mellitus with single photon emission computed tomography and coronary computed tomography angiography. Am J Cardiol 2009;104:890-896
-
(2009)
Am J Cardiol
, vol.104
, pp. 890-896
-
-
Choi, E.-K.1
Chun, E.J.2
Choi, S.-I.3
-
94
-
-
19644400972
-
Angiotensinconvertingenzyme inhibition in stable coronary artery disease
-
Braunwald E, Domanski MJ, Fowler SE, et al.; PEACE Trial Investigators. Angiotensinconvertingenzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068
-
(2004)
N Engl J Med
, vol.351
, pp. 2058-2068
-
-
Braunwald, E.1
Domanski, M.J.2
Fowler, S.E.3
-
95
-
-
53049109468
-
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in highrisk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial
-
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in highrisk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183
-
(2008)
Lancet
, vol.372
, pp. 1174-1183
-
-
-
96
-
-
84870163213
-
Beta blocker use after acute myocardial infarction in the patient with normal systolic function: When is it "ok" to discontinue?
-
Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue? Curr Cardiol Rev 2012;8:77-84
-
(2012)
Curr Cardiol Rev
, vol.8
, pp. 77-84
-
-
Kezerashvili, A.1
Marzo, K.2
De Leon, J.3
-
97
-
-
0016251063
-
Role of diabetes in congestive heart failure: The Framingham study
-
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34
-
(1974)
Am J Cardiol
, vol.34
, pp. 29-34
-
-
Kannel, W.B.1
Hjortland, M.2
Castelli, W.P.3
-
98
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
-
Dormandy JA, Charbonnel B, Eckland DJA, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.A.3
-
99
-
-
34548580881
-
Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis
-
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-1195
-
(2007)
JAMA
, vol.298
, pp. 1189-1195
-
-
Singh, S.1
Loke, Y.K.2
Furberg, C.D.3
-
100
-
-
34548590934
-
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
-
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188
-
(2007)
JAMA
, vol.298
, pp. 1180-1188
-
-
Lincoff, A.M.1
Wolski, K.2
Nicholls, S.J.3
Nissen, S.E.4
-
101
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
-
(2013)
N Engl J Med
, vol.369
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
-
102
-
-
84930085787
-
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial
-
Zannad F, Cannon CP, Cushman WC, et al.; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-2076
-
(2015)
Lancet
, vol.385
, pp. 2067-2076
-
-
Zannad, F.1
Cannon, C.P.2
Cushman, W.C.3
-
103
-
-
84937053742
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
-
Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
-
(2015)
N Engl J Med
, vol.373
, pp. 232-242
-
-
Green, J.B.1
Bethel, M.A.2
Armstrong, P.W.3
-
104
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, andmortality in type 2 diabetes
-
17 September, Epub ahead of print
-
Zinman B, Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, andmortality in type 2 diabetes. N Engl J Med. 17 September 2015 [Epub ahead of print]. DOI: 10.1056/NEJMoa1504720
-
(2015)
N Engl J Med.
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
105
-
-
84879207411
-
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34, 000 patients
-
Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34, 000 patients. Circ Heart Fail 2013;6:395-402
-
(2013)
Circ Heart Fail
, vol.6
, pp. 395-402
-
-
Eurich, D.T.1
Weir, D.L.2
Majumdar, S.R.3
|